The impact of liver transplantation on endpoint selection in alcohol-associated hepatitis trials

20251 citationsJournal Articlegold Open Access

Authors

Suthat Liangpunsakul · Indiana University School of Medicine

William B. Krebs

Allison J. Kwong · Stanford University

Paul Y. Kwo · Stanford University

Robert S. Brown · Cornell University

WeiQi Lin · Durect (United States)

Norman Sussman · Baylor College of Medicine

Abstract

The adoption of early LT complicates the assessment of new therapies for AH. Statistical methods and endpoints are critical in power calculations and when assessing the efficacy of new therapeutic agents. We recommend mortality as the primary analysis complemented by hierarchical secondary analyses that avoid problems of multiplicity.

Topics & Keywords

Alcohol Consumption and Health Effects Liver Disease Diagnosis and Treatment Diet, Metabolism, and Disease

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Hepatology Communications

Volume 9, Issue 5

DOI: 10.1097/hc9.0000000000000709

Field-Weighted Citation Impact: 1.48